2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab

P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab

Back to course

Pdf Summary

The study assesses the prognostic utility of peripheral myeloid cells for clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with cemiplimab, an anti-PD-1 therapy. Conducted by a team spanning institutions globally, the research utilized data from two phase 3 trials, EMPOWER-Lung 1 and 3. The research aimed to determine whether baseline hematological parameters like neutrophil/lymphocyte ratio (NLR), monocytes, and eosinophils could predict outcomes in NSCLC patients receiving cemiplimab with or without chemotherapy.<br /><br />A multivariable model was formulated and validated to explore the correlation between these blood cell counts and overall survival (OS). Higher NLR and monocyte levels were linked to an increased risk of death, whereas higher eosinophil levels signified a reduced risk. However, the prognostic capability of the model was moderate, with a concordance index of 0.61.<br /><br />Further, a Cox model-derived nomogram was developed to enable determination of 1-year and 2-year survival probabilities based on individual patient characteristics. Despite statistically significant findings, the moderate discrimination ability suggests more data are needed to improve clinical outcome predictions for NSCLC patients under cemiplimab treatment.<br /><br />The authors suggest that these baseline blood cell parameters might offer valuable insights for personalizing treatment plans, potentially enhancing dynamic decision-making in clinical settings. Patient demographics including age, sex, smoking status, and PD-L1 expression levels were meticulously detailed, confirming known eligibility differences.<br /><br />Overall, the study highlights the modest yet promising role of peripheral immune cell metrics in prognosticating NSCLC treatment outcomes, acknowledging that additional research is necessary for more precise predictions.

Asset Subtitle

Rolando Acosta

Meta Tag

Speaker Rolando Acosta

Topic Metastatic NSCLC – Immunotherapy

Keywords

prognostic utility

peripheral myeloid cells

non-small cell lung cancer

NSCLC

cemiplimab

anti-PD-1 therapy

neutrophil/lymphocyte ratio

overall survival

Cox model

personalizing treatment